Hourglass Capital LLC Sells 194 Shares of C.R. Bard, Inc. (BCR)

Hourglass Capital LLC cut its stake in C.R. Bard, Inc. (NYSE:BCR) by 11.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,483 shares of the medical instruments supplier’s stock after selling 194 shares during the period. Hourglass Capital LLC’s holdings in C.R. Bard were worth $469,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in BCR. Macquarie Group Ltd. raised its stake in C.R. Bard by 61.1% in the fourth quarter. Macquarie Group Ltd. now owns 5,800 shares of the medical instruments supplier’s stock valued at $1,303,000 after buying an additional 2,200 shares in the last quarter. Nisa Investment Advisors LLC raised its position in C.R. Bard by 0.8% in the first quarter. Nisa Investment Advisors LLC now owns 15,615 shares of the medical instruments supplier’s stock worth $3,881,000 after buying an additional 125 shares during the period. Quantitative Systematic Strategies LLC purchased a new position in C.R. Bard during the first quarter worth about $219,000. Huntington National Bank raised its position in C.R. Bard by 8.4% in the first quarter. Huntington National Bank now owns 16,411 shares of the medical instruments supplier’s stock worth $4,079,000 after buying an additional 1,278 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in C.R. Bard during the first quarter worth about $1,929,000. Institutional investors and hedge funds own 77.14% of the company’s stock.

C.R. Bard, Inc. (NYSE BCR) traded down 0.30% during mid-day trading on Friday, reaching $318.20. 431,723 shares of the company were exchanged. The company has a market cap of $23.12 billion, a P/E ratio of 41.77 and a beta of 0.59. The stock’s 50-day moving average is $319.58 and its 200-day moving average is $286.55. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. During the same period last year, the company posted $2.54 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Equities analysts expect that C.R. Bard, Inc. will post $11.82 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Shareholders of record on Monday, July 24th were given a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. C.R. Bard’s payout ratio is presently 13.67%.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by [[site]] and is owned by of [[site]]. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at [[permalink]].

A number of research analysts have issued reports on the stock. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. Zacks Investment Research lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub lowered shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, BMO Capital Markets restated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. C.R. Bard currently has a consensus rating of “Hold” and an average target price of $285.67.

In other news, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.80% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).